In vivo toxicity, pharmacokinetic features and tissue distribution of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236), a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase
- PMID: 11505789
- DOI: 10.1055/s-0031-1300082
In vivo toxicity, pharmacokinetic features and tissue distribution of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236), a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase
Abstract
N-[2-(2,5-Dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236, CAS 233271-65-3) possesses potent anti-viral activity against zidovudine-sensitive as well as multidrug-resistant HIV-1 (human immunodeficiency virus) strains. The purpose of the present study was to examine in vivo toxicity, pharmacokinetic features and tissue distribution of HI-236 in mice. HI-236 had an elimination half-life of 85.8 min after i.v. administration and 86.6 min after i.p. administration. The systemic clearance of HI-236 was 4337 ml/h/kg after i.v. administration and 10,130 ml/h/kg after i.p. administration. Following i.v. injection, HI-236 rapidly distributed to and accumulated in multiple tissues with particularly high accumulation in lung, adipose tissue, skin, urinary bladder, adrenal gland and uterus + ovary. The concentration of HI-236 in brain tissue was comparable to that in the plasma, indicating that HI-236 easily crosses the blood-brain barrier. Following i.p. injection, HI-236 was rapidly absorbed with a tmax values of 5.6 min and showed linear pharmacokinetics within the dose range of 10-80 mg/kg. Following oral administration, HI-236 was absorbed with a tmax of 5.8 min. The intraperitoneal bioavailability was estimated at 42.9%, while the oral bioavailability was only 2.2%. The pharmacokinetic study described herein provides the basis for advanced pharmacodynamic study of HI-236.
Similar articles
-
Evaluation of the pharmacokinetic features and tissue distribution of the potent nonnucleoside inhibitor of HIV-1 reverse transcriptase, N-[2-(2-fluorophenethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-240) with an analytical HPLC method.Pharm Res. 1999 Aug;16(8):1226-32. doi: 10.1023/a:1014814313681. Pharm Res. 1999. PMID: 10468024
-
In vivo pharmacokinetics, metabolism, toxicity, and anti-HIV activity of N'-[2-(2-Thiophene)ethyl]-N'-[2-(5-bromopyridyl)]thiourea (HI-443), a potent non-nucleoside inhibitor of HIV reverse transcriptase.Arzneimittelforschung. 2007;57(7):483-96. doi: 10.1055/s-0031-1296636. Arzneimittelforschung. 2007. PMID: 17803063
-
In vivo pharmacokinetics and toxicity of a novel hydrophilic oral formulation of the potent non-nucleoside reverse transcriptase inhibitor compound N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea (HI-443).Arzneimittelforschung. 2007;57(4):218-26. doi: 10.1055/s-0031-1296608. Arzneimittelforschung. 2007. PMID: 17515292
-
A novel vaginal microbicide containing the rationally designed anti-HIV compound HI-443 (N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea]).Expert Opin Investig Drugs. 2012 Mar;21(3):265-79. doi: 10.1517/13543784.2012.655422. Epub 2012 Feb 1. Expert Opin Investig Drugs. 2012. PMID: 22292483 Review.
-
Compared plasma and brain pharmacokinetics of clomipramine and its metabolite demethylclomipramine in two strains of mice (NMRI and CD1).Fundam Clin Pharmacol. 1992;6(2):49-57. doi: 10.1111/j.1472-8206.1992.tb00094.x. Fundam Clin Pharmacol. 1992. PMID: 1607145 Review.
Cited by
-
Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms.J Virol. 2013 Jul;87(14):8017-28. doi: 10.1128/JVI.00998-13. Epub 2013 May 15. J Virol. 2013. PMID: 23678171 Free PMC article.
-
C-2-aryl O-substituted HI-236 derivatives as non-nucleoside HIV-1 reverse-transcriptase inhibitors.Bioorg Med Chem. 2008 Dec 15;16(24):10270-80. doi: 10.1016/j.bmc.2008.10.048. Epub 2008 Nov 1. Bioorg Med Chem. 2008. PMID: 18996020 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
